| The Role of Nutraceuticals in Statin Intolerant Patients | Journal of the American College of Cardiology | 2018 | 157 |
| Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM | Clinical Chemistry | 2018 | 124 |
| Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) | Atherosclerosis | 2018 | 93 |
| Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics | European Heart Journal | 2018 | 90 |
| MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy | Trends in Pharmacological Sciences | 2018 | 40 |
| Simplified Canadian Definition for Familial Hypercholesterolemia | Canadian Journal of Cardiology | 2018 | 36 |
| A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia | Journal of Clinical Endocrinology and Metabolism | 2018 | 30 |
| Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials | Drugs | 2018 | 30 |
| Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis | Clinical Cardiology | 2018 | 23 |
| Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part | Atherosclerosis | 2018 | 22 |
| Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal | Journal of Clinical Lipidology | 2018 | 20 |
| Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease | Journal of Clinical Lipidology | 2018 | 19 |
| In search of the vulnerable patient or the vulnerable plaque: F-sodium fluoride positron emission tomography for cardiovascular risk stratification | Journal of Nuclear Cardiology | 2018 | 19 |
| PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease | Diabetes, Obesity and Metabolism | 2018 | 18 |
| Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey | European Heart Journal | 2018 | 18 |
| Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience | Clinical Cardiology | 2018 | 17 |
| Catheter-based renal denervation: the next chapter begins | European Heart Journal | 2018 | 15 |
| Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque | Atherosclerosis | 2018 | 13 |
| Parent-child genetic testing for familial hypercholesterolaemia in an Australian context | Journal of Paediatrics and Child Health | 2018 | 11 |
| Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic? | Cardiology Clinics | 2018 | 10 |
| TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol | BMJ Open | 2018 | 10 |
| Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia | Atherosclerosis | 2018 | 10 |
| Rationale and design of a trial to personalize risk assessment in familial coronary artery disease | American Heart Journal | 2018 | 9 |
| Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL-6 production | Immunology and Cell Biology | 2018 | 9 |
| Pharmacotherapeutic strategies for treating hypertension in patients with obesity | Expert Opinion on Pharmacotherapy | 2018 | 8 |
